Nearly a Quarter of Postmarket Trial Annual Reports Were Late or Not Filed in Fiscal 2020

Sponsors are still not where they should be on meeting postmarket trial requirements and commitments, the FDA’s latest analysis shows: 24 percent of annual status reports for required or agreed upon postmarket trials were either late or unfiled in fiscal 2020.
Source: Drug Industry Daily